Search

Your search keyword '"Bertoli, Sarah"' showing total 476 results

Search Constraints

Start Over You searched for: Author "Bertoli, Sarah" Remove constraint Author: "Bertoli, Sarah"
476 results on '"Bertoli, Sarah"'

Search Results

1. Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study

2. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study

3. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study

4. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms

6. Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS

7. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia

8. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study

10. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO

11. Overlapping features of therapy-related and de novo NPM1-mutated AML

12. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group

13. Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.

14. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

16. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

18. Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia

19. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

20. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

21. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

22. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome

23. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.

25. Genomic landscape of hyperleukocytic acute myeloid leukemia

26. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients

27. Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

30. Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

31. Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

32. Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia

34. PB1764: SEGMENTATION AND CLASSIFICATION OF BONE MARROW CELLS FROM MULTI-PRECISION NUMERIZATION OF BONE MARROW SMEARS (BMS) FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) USING AI TECHNIQUES

36. Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites

38. Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy.

39. Data from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia

40. Supplementary Information v.2 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia

41. Supplementary Figures S1-S22 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia

42. Clinico‐biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi‐centric observational study

43. Supplementary Table S15 from C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia

46. C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis inFLT3-Mutant Leukemia

47. Data from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

48. Supplementary Figure 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

49. Supplementary Figures S1-S7 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia

50. Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Catalog

Books, media, physical & digital resources